EPI-hNE4, a proteolysis-resistant inhibitor of human neutrophil elastase and potential anti-inflammatory drug for treating cystic fibrosis

Journal of Pharmacology and Experimental Therapeutics

Volumn 318, Issue 2, 2006, Pages 803-809

  Attucci, Sylvie ^a   Gauthier, Alexandre ^a   Korkmaz, Brice ^a   Delépine, Pascal ^b   Ferrer Di Martino, Michèle ^a   Saudubray, François ^c   Diot, Patrice ^a   Gauthier, Francis ^a  

^a UNIVERSITÉ DE TOURS   (France)

^b UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^c DEBIOPHARM SA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CATHEPSIN G; DEPELSTAT; GELATINASE B; LEUKOCYTE ELASTASE INHIBITOR; MATRIX METALLOPROTEINASE; NEUTROPHIL COLLAGENASE; PEPSIN A; PROTEINASE ACTIVATED RECEPTOR 3; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROLYSIS; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN DEGRADATION; SPUTUM ANALYSIS;

EID: 33745941917     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.103440     Document Type: Article

References (41)

1. Attucci S, Korkmaz B, Juliano L, Hazouard E, Girardin C, Brillard-Bourdet M, Rehault S, Anthonioz P, and Gauthier F (2002) Measurement of free and membrane-bound cathepsin G in human neutrophils using new sensitive fluorogenic substrates. Biochem J 366:965-970.
2. Becher F, Pruvost A, Clement G, Tabet JC, and Ezan E (2006) Quantification of small therapeutic proteins in plasma by liquid chromatography-tandem mass spectrometry: application to an elastase inhibitor EPI-hNE4. Anal Chem 78:2306-2313.
3. Birrer P, McElvaney NG, Rudeberg A, Sommer CW, Liechti-Gallati S, Kraemer R, Hubbard R, and Crystal RG (1994) Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med 150:207-213.
4. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch Y, and Zychlinsky A (2004) Neutrophil extracellular traps kill bacteria. Science (Wash DC) 303:1532-1535.
5. Campbell EJ, Campbell MA, and Owen CA (2000) Bioactive proteinase 3 on the cell surface of human neutrophils: quantification, catalytic activity and susceptibility to inhibition. J Immunol 165:3366-3374.
6. Chan SC, Shum DK, and Ip MS (2003) Sputum sol neutrophil elastase activity in bronchiectasis: differential modulation by syndecan-1. Am J Respir Crit Care Med 168:192-198.
7. Chughtai B and O'Riordan TG (2004) Potential role of inhibitors of neutrophil elastase in treating diseases of the airway. J Aerosol Med 17:289-298.
8. De Rose V (2002) Mechanisms and markers of airway inflammation in cystic fibrosis. Eur Respir J 19:333-340.
9. Delacourt C, Herigault S, Delclaux C, Poncin A, Levame M, Harf A, Saudubray F, and Lafuma C (2002) Protection against acute lung injury by intravenous or intratracheal pretreatment with EPI-HNE-4, a new potent neutrophil elastase inhibitor. Am J Respir Cell Mol Biol 26:290-297.
10. 1-antichymotrypsin by oxidatively activated human neutrophil metalloproteinases. J Biol Chem 267:5005-5012.
11. Dunsmore SE, Saarialho-Kere UK, Roby JD, Wilson CL, Matrisian LM, Welgus HG, and Parks WC (1998) Matrilysin expression and function in airway epithelium. J Clin Investig 102:1321-1331.
12. Fahy JV, Schuster A, Ueki I, Boushey HA, and Nadel JA (1992) Mucus hypersecretion in bronchiectasis: the role of neutrophil proteases. Am Rev Respir Dis 146:1430-1433.
13. Fujita J, Skold CM, Daughton DM, Ertl RF, Takahara J, and Rennard SI (1999) Modulation of elastase binding to elastin by human alveolar macrophage-derived lipids. Am J Respir Crit Care Med 160:802-807.
14. 1-protease inhibitor in cystic fibrosis. Electrophoresis 22:165-171.
15. Grimbert D, Vecellio L, Delepine P, Attucci S, Boissinot E, Poncin A, Gauthier F, Valat C, Saudubray F, Antonioz P, et al. (2003) Characteristics of EPI-hNE4 aerosol: a new elastase inhibitor for treatment of cystic fibrosis. J Aerosol Med 16:121-129.
16. Heinzel-Wieland R, Steffens GJ, and Flohe L (1991) Inhibitory characteristics and oxidant resistance of site specific variants of recombinant human antileukoproteinase (ALP). Biomed Biochim Acta 50:677-681.
17. Honore S, Attalah HL, Azoulay E, Soussy CJ, Saudubray F, Harf A, Brochard L, and Delclaux C (2004) Beneficial effect of an inhibitor of leukocyte elastase (EPIhNE-4) in presence of repeated lung injuries. Shock 22:131-136.
18. Konstan MW and Davis PB (2002) Pharmacological approaches for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosis. Adv Drug Deliv Rev 54:1409-1423.
19. 1-protease inhibitor at the surface of human polymorphonuclear neutrophils. J Immunol 175:3329-3338.
20. Korkmaz B, Attucci S, Moreau T, Godat E, Juliano L, and Gauthier F (2004) Design and use of highly specific substrates of neutrophil elastase and proteinase 3. Am J Respir Cell Mol Biol 30:801-807.
21. 1-antitrypsin treatment for cystic fibrosis. Lancet 337:392-394.
22. McElvaney NG, Nakamura H, Birrer P, Hebert CA, Wong WL, Alphonso M, Baker JB, Catalano MA, and Crystal RG (1992) Modulation of airway inflammation in cystic fibrosis: in vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Investig 90:1296-1301.
23. Moraes TJ, Chow CW, and Downey GP (2003) Proteases and lung injury. Crit Care Med 31:S189-S194.
24. O'Riordan TG, Otero R, Mao Y, Lauredo I, and Abraham WM (1997) Elastase contributes to antigen-induced mucociliary dysfunction in ovine airways. Am J Respir Crit Care Med 155:1522-1528.
25. Ohbayashi H (2002) Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs 11:965-980.
26. Owen CA and Campbell EJ (1995) Neutrophil proteinases and matrix degradation: the cell biology of pericellular proteolysis. Semin Cell Biol 6:367-376.
27. Owen CA, Campbell MA, Sannes PL, Boukedes SS, and Campbell EJ (1995) Cell surface-bound elastase and cathepsin G on human neutrophils: a novel, nonoxidative mechanism by which neutrophils focus and preserve catalytic activity of serine proteinases. J Cell Biol 131:775-789.
28. 1-proteinase inhibitor by selected bacterial proteinases. Biol Chem 380:1211-1216.
29. Ratjen F, Hartog CM, Paul K, Wermelt J, and Braun J (2002) Matrix metalloproteases in BAL fluid of patients with cystic fibrosis and their modulation by treatment with dornase α. Thorax 57:930-934.
30. Roberts BL, Markland W, Ley AC, Kent RB, White DW, Guterman SK, and Ladner RC (1992) Directed evolution of a protein: selection of potent neutrophil elastase inhibitors displayed on M13 fusion phage. Proc Natl Acad Sci USA 89:2429-2433.
31. Rosenberg S, Barr PJ, Najarian RC, and Hallewell RA (1984) Synthesis in yeast of a functional oxidation-resistant mutant of human α-antitrypsin. Nature (Lond) 312:77-80.
32. Schuster A, Hansen G, Zubrod-Eichert C, and Wahn V (1996) Effects of native and oxidation-resistant secretory leukoprotease inhibitor on cystic fibrosis sputum: inhibition of neutrophil elastase activity and of sputum-induced secretion from porcine tracheal submucosal glands. Pediatr Res 40:732-737.
33. Shapiro SD (2002) Neutrophil elastase: path clearer, pathogen killer, or just pathologic? Am J Respir Cell Mol Biol 26:266-268.
34. 1-antitrypsin. Biochem Biophys Res Commun 204:613-620.
35. Sponer M, Nick HP, and Schnebli HP (1991) Different susceptibility of elastase inhibitors to inactivation by proteinases from Staphylococcus aureus and Pseudomonas aeruginosa. Biol Chem Hoppe-Seyler 372:963-970.
36. 1-proteinase inhibitor in infected bronchial secretions from patients with cystic fibrosis. Eur Respir J 4:40-49.
37. Suter S, Schaad UB, Morgenthaler JJ, Chevallier I, and Schnebli HP (1988) Fibronectin-cleaving activity in bronchial secretions of patients with cystic fibrosis. J Infect Dis 158:89-100.
38. Vandivier RW, Fadok VA, Hoffmann PR, Bratton DL, Penvari C, Brown KK, Brain JD, Accurso FJ, and Henson PM (2002) Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis. J Clin Investig 109:661-670.
39. Venaille TJ, Ryan G, and Robinson BW (1998) Epithelial cell damage is induced by neutrophil-derived, not pseudomonas-derived, proteases in cystic fibrosis sputum. Respir Med 92:233-240.
40. Witko-Sarsat V, Halbwachs-Mecarelli L, Schuster A, Nusbaum P, Ueki I, Canteloup S, Lenoir G, Descamps-Latscha B, and Nadel JA (1999) Proteinase 3, a potent secretagogue in airways, is present in cystic fibrosis sputum. Am J Respir Cell Mol Biol 20:729-736.
41. Zani ML, Nobar SM, Lacour SA, Lemoine S, Boudier C, Bieth JG, and Moreau T (2004) Kinetics of the inhibition of neutrophil proteinases by recombinant elafin and pre-elafin (trappin-2) expressed in Pichia pastoris. Eur J Biochem 271:2370-2378.